These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2417649)

  • 1. A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
    Ramsay JW; Scott GI; Whitfield HN
    Br J Urol; 1985 Dec; 57(6):657-9. PubMed ID: 2417649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder outflow obstruction treated with phenoxybenzamine.
    Abrams PH; Shah PJ; Stone R; Choa RG
    Prog Clin Biol Res; 1981; 78():269-75. PubMed ID: 6174998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoramin in the treatment of prostatic bladder outflow obstruction.
    Stott MA; Abrams P
    Br J Urol; 1991 May; 67(5):499-501. PubMed ID: 1710162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder outflow obstruction treated with phenoxybenzamine.
    Abrams PH; Shah PJ; Stone R; Choa RG
    Br J Urol; 1982 Oct; 54(5):527-30. PubMed ID: 6184106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation.
    Ronchi F; Margonato A; Ceccardi R; Rigatti P; Rossini BM
    Urol Res; 1982; 10(3):131-4. PubMed ID: 6182672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and side-effects of prazosin as a symptomatic treatment of benign prostatic obstruction.
    Ruutu ML; Hansson E; Juusela HE; Permi JE; Rusk JI; Sotarauta MT; Talja MT; Wuokko EJ; Mattila MJ
    Scand J Urol Nephrol; 1991; 25(1):15-9. PubMed ID: 1710823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of benign prostatic hyperplasia with phytosterols.
    Carbin BE; Larsson B; Lindahl O
    Br J Urol; 1990 Dec; 66(6):639-41. PubMed ID: 1702340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study.
    Buck AC; Cox R; Rees RW; Ebeling L; John A
    Br J Urol; 1990 Oct; 66(4):398-404. PubMed ID: 1699628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoramin--an effective new drug in the management of bladder outflow obstruction.
    Iacovou JW; Dunn M
    Br J Urol; 1987 Dec; 60(6):526-8. PubMed ID: 2447995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
    Song K; Choo MS; Lee KS; Han JY; Lee YS; Kim JC; Cho JS
    Urology; 2011 May; 77(5):1177-82. PubMed ID: 21256567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study.
    Kirby RS; Coppinger SW; Corcoran MO; Chapple CR; Flannigan M; Milroy EJ
    Br J Urol; 1987 Aug; 60(2):136-42. PubMed ID: 2444306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction.
    Caine M; Perlberg S; Meretyk S
    Br J Urol; 1978 Dec; 50(7):551-4. PubMed ID: 88984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
    De Nunzio C; Franco G; Iori F; Leonardo C; Minardi V; Laurenti C
    Urol Int; 2003; 71(1):31-6. PubMed ID: 12845257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
    Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P
    Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
    Kirby RS
    Urology; 1995 Aug; 46(2):182-6. PubMed ID: 7542819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.